Proresolving lipid mediators and liver disease

Biochim Biophys Acta Mol Cell Biol Lipids. 2021 Nov;1866(11):159023. doi: 10.1016/j.bbalip.2021.159023. Epub 2021 Aug 2.

Abstract

Inflammation is a characteristic feature of virtually all acute and chronic liver diseases. It intersects different liver pathologies from the early stages of liver injury, when the inflammatory burden is mild-to-moderate, to very advanced stages of liver disease, when the inflammatory response is very intense and drives multiple organ dysfunction and failure(s). The current review describes the most relevant features of the inflammatory process in two different clinical entities across the liver disease spectrum, namely non-alcoholic steatohepatitis (NASH) and acute-on-chronic liver failure (ACLF). Special emphasis is given within these two disease conditions to gather the most relevant data on the specialized pro-resolving mediators that orchestrate the resolution of inflammation, a tightly controlled process which dysregulation commonly associates with chronic inflammatory conditions.

Keywords: Leukocytes; Lipid mediators; Liver disease; Specialized pro-resolving mediators; Systemic inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Inflammation / metabolism
  • Inflammation Mediators / metabolism*
  • Lipid Metabolism
  • Liver Diseases / metabolism*

Substances

  • Inflammation Mediators